Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Mulhouse – page 33

713 clinical trials in Mulhouse, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Mulhouse at a glance
713
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

713 trials in Mulhouse

Open in trial search

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetapir (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetapir (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Mulhouse

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and colorectal cancer treatments, evaluating novel therapeutic combinations and immunotherapy approaches.

  • Multiple Myeloma Treatment Innovation
  • Advanced NSCLC Therapies
  • Metastatic Cancer Management

Clinical trials investigating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Studies examining treatments for Sjögren's Syndrome and Systemic Lupus Erythematosus, with emphasis on innovative therapeutic approaches.

  • Novel Biologics Development
  • Disease Activity Management
  • Long-term Safety Studies

Research focused on improving quality of life for patients with chronic autoimmune conditions.

03 Respiratory Medicine

Investigating treatments for COPD and pulmonary infections, including studies on inhalation therapies and antimicrobial treatments.

  • COPD Management
  • Pulmonary Infection Treatment
  • Respiratory Drug Delivery

Clinical research aimed at enhancing respiratory health outcomes through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.